Biotech Firm JACOBIO-B Anticipates First-Ever Profit of at Least RMB 600 Million

Stock News

Aug 10

JACOBIO-B (01167) has issued a profit alert, forecasting a net profit of no less than RMB 600 million for the six months ending June 30, 2026. This marks a sharp turnaround from a net loss of approximately RMB 58.99 million recorded in the same period a year earlier, and represents the company's first-ever profitable period.

The shift from loss to profit is primarily attributed to a significant surge in revenue. Key contributors include: (1) income from a strategic licensing agreement with AstraZeneca AB for the global (excluding China, Hong Kong SAR, Macau SAR, and Taiwan) research, development, manufacturing, and commercialization of JAB-23E73 (pan-KRAS); and (2) revenue from licensing and service agreements with Shanghai Allist Pharmaceuticals Co., Ltd. for the research, development, manufacturing, and commercialization of Ailekay® (glecirasib, KRAS G12C) and sitneprotafib (JAB-3312, SHP2) in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1162483114"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162483114\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162483114?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162483114","market":"sg","top_or_hot":-1,"title":"Biotech Firm JACOBIO-B Anticipates First-Ever Profit of at Least RMB 600 Million","media":"Stock News","content":"<p><b>JACOBIO-B (01167)</b> has issued a profit alert, forecasting a net profit of no less than RMB 600 million for the six months ending June 30, 2026. This marks a sharp turnaround from a net loss of approximately RMB 58.99 million recorded in the same period a year earlier, and represents the company's first-ever profitable period.<br><br>The shift from loss to profit is primarily attributed to a significant surge in revenue. Key contributors include: (1) income from a strategic licensing agreement with AstraZeneca AB for the global (excluding China, Hong Kong SAR, Macau SAR, and Taiwan) research, development, manufacturing, and commercialization of JAB-23E73 (pan-KRAS); and (2) revenue from licensing and service agreements with Shanghai Allist Pharmaceuticals Co., Ltd. for the research, development, manufacturing, and commercialization of Ailekay® (glecirasib, KRAS G12C) and sitneprotafib (JAB-3312, SHP2) in China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Firm JACOBIO-B Anticipates First-Ever Profit of at Least RMB 600 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Firm JACOBIO-B Anticipates First-Ever Profit of at Least RMB 600 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-10 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>JACOBIO-B (01167)</b> has issued a profit alert, forecasting a net profit of no less than RMB 600 million for the six months ending June 30, 2026. This marks a sharp turnaround from a net loss of approximately RMB 58.99 million recorded in the same period a year earlier, and represents the company's first-ever profitable period.<br><br>The shift from loss to profit is primarily attributed to a significant surge in revenue. Key contributors include: (1) income from a strategic licensing agreement with AstraZeneca AB for the global (excluding China, Hong Kong SAR, Macau SAR, and Taiwan) research, development, manufacturing, and commercialization of JAB-23E73 (pan-KRAS); and (2) revenue from licensing and service agreements with Shanghai Allist Pharmaceuticals Co., Ltd. for the research, development, manufacturing, and commercialization of Ailekay® (glecirasib, KRAS G12C) and sitneprotafib (JAB-3312, SHP2) in China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1162483114","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162483114","pubTimestamp":1786363225,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JACOBIO-B (01167) has issued a profit alert, forecasting a net profit of no less than RMB 600 million for the six months ending June 30, 2026. This marks a sharp turnaround from a net loss of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01167":"加科思-B","BK1574":"生物医药B类股"},"translate_title":"生物技术公司JACOBIO-B预计首次盈利至少6亿元人民币","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"JACOBIO-B (01167) has issued a profit alert, forecasting a net profit of no less than RMB 600 million for the six months ending June 30, 2026. This marks a sharp turnaround from a net loss of approximately RMB 58.99 million recorded in the same period a year earlier, and represents the company's first-ever profitable period.The shift from loss to profit is primarily attributed to a significant surge in revenue. Key contributors include: (1) income from a strategic licensing agreement with AstraZeneca AB for the global (excluding China, Hong Kong SAR, Macau SAR, and Taiwan) research, development, manufacturing, and commercialization of JAB-23E73 (pan-KRAS); and (2) revenue from licensing and service agreements with Shanghai Allist Pharmaceuticals Co., Ltd. for the research, development, manufacturing, and commercialization of Ailekay® (glecirasib, KRAS G12C) and sitneprotafib (JAB-3312, SHP2) in China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}